OHB's Cosmic Irony: A Space-Station Health Breakthrough Overshadowed by a 72% Slide

OHB shares fall 72% from May peak amid sector-wide space sell-off, yet order book and revenue growth remain robust with 2026 guidance intact.

There is a certain cosmic irony in the fact that OHB SE is currently developing technology to combat muscle atrophy in zero gravity, while its own share price is experiencing a bout of severe weightlessness. The Bremen-based space group this week qualified a training suit for a six-week ESA experiment aboard the International Space Station — a project designed to keep astronaut Sophie Adenot's muscles from wasting away in orbit. Back on Earth, investors are watching a different kind of deterioration: the stock has now fallen 72 percent from its May record high of €688.00, and the descent shows no immediate signs of slowing.

The juxtaposition is stark. On Tuesday, OHB shares shed another 2.8 percent, marking the kind of steady erosion that has become the company's unwanted signature in recent weeks. The stock has now fallen for five consecutive trading days, making it the worst performer in the SDAX on Monday. Yet the operational story could hardly be more different. The company's order book sits in the double-digit billions, revenue growth is running at roughly 20 percent, and management confirmed its 2026 guidance in August — targeting total output of €1.4 billion with an adjusted EBITDA margin of 10.5 to 11 percent.

A Sector-Wide Correction, Not a Company-Specific Crisis

The root of the sell-off appears to be external rather than internal. The May rally that propelled OHB to its record high was part of a broader space-sector euphoria triggered by the SpaceX initial public offering. That sentiment has now reversed with a vengeance — SpaceX itself has fallen below its own IPO price since peaking in mid-June, dragging the entire sector down with it. OHB, which had moved in close tandem with SpaceX since spring, has been caught in the same downdraft.

The fundamental picture, however, remains robust. OHB's half-year results, published in August, showed total output of €628 million and adjusted EBITDA of €60 million — an increase of more than 30 percent year-on-year. The order book has reached a record high, and the pipeline of potential new projects stands at approximately €20 billion, according to company statements. Mid-August brought additional good news: reports that OHB had secured a major contract for 18 satellites under the EU's Iris2 project, valued at around €1 billion. The company also won an order from the Italian space agency ASI for the second generation of the PRISMA mission, a project running through the end of 2031.

Fresh Capital, Old Questions

The recent capital increase — which attracted more than 200 investors, 94 percent of them institutional — was initially viewed as a vote of confidence. Yet the new shares traded down noticeably on their first day, a pattern familiar to growth stories that have run too hot too quickly. The 50-day moving average now sits at €269.11, with the current price roughly 27 percent below that level — a technical picture that some chart-oriented investors might read as oversold.

Several analysts published their first price targets for the stock in early August, ranging from €250 to €360, all comfortably above current trading levels. The gap between operational performance and market valuation is wide enough that, should the selling pressure ease, bargain hunters could step in. The question is whether positive news will finally begin to stick. So far, both the SDAX inclusion in mid-August and the Iris2 announcement provided only brief bounces before gains were quickly surrendered — a sign that good news is currently being sold, not bought.

The SpaceX Shadow

The uncomfortable truth for OHB shareholders is that the company's fate appears increasingly tied to perceptions of its American counterpart. As long as the broader space sector remains under pressure, OHB is likely to be dragged along regardless of its own contract wins. The volatility of recent weeks reflects a market environment in which investors are treating fundamental news as secondary to sector momentum.

The immediate catalyst to watch remains SpaceX. Should the sector leader stabilize, OHB could follow suit. But if the correction deepens, even a €20 billion pipeline and a confirmed guidance may not be enough to halt the slide. For now, the company's space-station training suit is designed to prevent muscle loss in astronauts. At the current rate, OHB's shareholders might wish for a similar stabilization program of their own.